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Muscle cell differentiation caused a reduction of glu-
cose transport, GLUT1 glucose transporter expression,
and GLUT1 mRNA levels. A fragment of 2.1 kilobases of
the rat GLUT1 gene linked to chloramphenicol acetyl-
transferase drove transcriptional activity in myoblasts,
and differentiation caused a decrease in transcription.
Transient transfection of 5* and 3* deletion constructs
showed that the fragment 299/233 of the GLUT1 gene
drives transcriptional activity of the GLUT1 gene and
participates in the reduced transcription after muscle
differentiation. Electrophoretic mobility shift assays
showed the binding of Sp1 protein to the fragment 2102/
237 in the myoblast state but not in myotubes, and Sp1
was found to transactivate the GLUT1 promoter. West-
ern blot analysis indicated that Sp1 was drastically
down-regulated during myogenesis. Furthermore, the
forced over-expression of MyoD in C3H10T1/2 cells mim-
icked the effects observed during myogenesis, Sp1
down-regulation and reduced transcriptional activity of
the GLUT1 gene promoter.
In all, these data suggest a regulatory model in
which MyoD activation during myogenesis causes the
down-regulation of Sp1, which contributes to the re-
pression of GLUT1 gene transcription and, therefore,
leads to the reduction in GLUT1 expression and glucose
transport.
The formation of skeletal muscle during embryogenesis in-
volves, first, commitment of mesodermal stem cells to the myo-
genic lineage. Myoblast cells, although undifferentiated and
capable of continued proliferation, differentiate when they re-
ceive the appropriate environmental signals, fuse, and form
multinucleate myotubes. At the same time as this morpholog-
ical differentiation, a battery of adult muscle-specific genes
whose products are required for the unique contractile and
metabolic properties of the muscle fiber are activated (1, 2). The
factors that regulate the expression of muscle-specific genes
following commitment to terminal differentiation are well es-
tablished. The best characterized are the members of the myo-
genic basic helix-loop-helix (bHLH)1 protein family or MyoD
family, that function as master regulators of muscle cell fate
during development (2, 3). Four members of the family have
been cloned: MyoD (4), Myf5 (5), myogenin (6, 7), and Mrf4
(8–10). Each of these factors is expressed exclusively in skele-
tal muscle, and when expressed ectopically in a variety of
non-muscle cell types, they activate the complete program of
myogenic differentiation (2). All the members of the myogenic
bHLH family activate the transcription of muscle-specific
genes by binding to the E-box consensus sequence (CANNTG)
in muscle gene promoters and enhancers. However, not all
muscle genes contain functional E boxes in their regulatory
promoter regions, and myogenic bHLH proteins can also acti-
vate transcription of muscle-specific genes that lack E boxes in
their control regions (3). As expected, from these data, other
muscle-specific transcription factors have been described to
function as intermediates in the activation of gene expression
during myogenesis, such as the M-CAT binding factor (11), and
the myocyte enhancer factor 2 (MEF2) (12, 13).
Myogenesis is also associated with down-regulation of sev-
eral growth-regulated myoblast proteins, including c-Fos (14),
b- and g-actins (15, 16), and the differentiation inhibitor (Id)
(17). In contrast to the wealth of information regarding the
mechanisms that activate genes participating in the myotube
phenotype, relatively little is known regarding regulatory se-
quences or factors involved in the control of the repression of
the muscle embryo genes during muscle cell differentiation.
Thus, it has been described that an activating transcription
factor site is required for the expression of the Id2A gene in
muscle cells, and that the binding of nuclear factors to the
activating transcription factor site is decreased during myo-
genic differentiation (18).
Glucose transporter expression is developmentally regulated
in skeletal muscle (19, 20). Thus, during fetal and early post-
natal life, GLUT1 is highly expressed in heart and skeletal
muscles. Postnatal life is characterized by GLUT1 repression
in muscle, which is concomitant with the induction of GLUT4
expression (19). Similarly, it has been reported that myogen-
esis leads to induction of GLUT4 expression and repression of
GLUT1 expression (21, 22). Based on the fact that congenital
hypothyroidism partially blocks GLUT1 repression associated
with neonatal life (23) and that denervation up-regulates
GLUT1 in skeletal muscle (20, 24–26), it is likely that thyroid
hormones and muscle innervation play a role in the regulation
of muscle GLUT1 expression in vivo. However, the detailed
mechanisms that contribute to GLUT1 repression during peri-
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natal development and myogenesis are largely unknown. Here
we have examined the mechanisms that repress GLUT1 ex-
pression during myogenesis.
EXPERIMENTAL PROCEDURES
Materials—125I-labeled protein A and [a-32P]-dCTP were purchased
from ICN. 2-Deoxy-D-[3H]glucose was obtained from DuPont NEN. Hy-
bond N was from Amersham Corp., and random primed DNA labeling
kit was from Boehringer Mannheim. Immobilon was obtained from
Millipore Corp. g-Globulin and most commonly used chemicals were
from Sigma. Dulbecco’s modified Eagle’s medium (DMEM), fetal-bovine
serum, glutamine, and antibiotics were obtained from Whittaker
(Walkersville, MD). L6E9 rat skeletal muscle cell line was kindly pro-
vided by Dr. B. Nadal-Ginard (Harvard University). C3H10T1/2 mouse
cells stably transfected with MyoD were obtained from Dr. V. Andrés
(St. Elizabeth’s Medical Center, Boston).
The plasmid containing the 22106/1134 region of the rat GLUT1
genomic sequence was obtained from Dr. M. Birnbaum (University of
Pennsylvania). pCAT-basic vector was obtained from Promega (Madi-
son, WI). pCMV-b-galactosidase vector was obtained from Dr. N. Brand
(National Heart & Lung Institute, London). Plasmid CMV-Sp1 was a
generous gift of Dr. R. Tjian (University of California, Berkeley).
Cell Culture and Preparation of Membrane Fractions—Rat skeletal
muscle L6E9 myoblasts were grown in monolayer culture in DMEM
supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) antibiotics
(10,000 units/ml penicillin G and 10 mg/ml streptomycin), 2 mM gluta-
mine, and 25 mM Hepes, pH 7.4. Confluent myoblasts were differenti-
ated by lowering fetal bovine serum to a final concentration of 2% (v/v).
Mouse C3H10T1/2 fibroblasts stably transfected with MyoD were
grown as L6E9 cells in the presence of 0.5 mg/ml geneticin and differ-
entiated in DMEM containing 5% (v/v) horse serum with antibiotics and
geneticin.
Cells were washed 2 times with PBS, scraped, and homogenized in 2
ml of ice-cold buffer containing 25 mM Hepes, 250 mM sucrose, 4 mM
EDTA, 1 trypsin inhibitor unit/ml of aprotinin, 25 mM benzamidine, 0.2
mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, and 1 mM pepstatin,
pH 7.4, using a Dounce A homogenizer. Homogenates were processed as
previously reported (27). Proteins were measured by the method of
Bradford (28) using g-globulin as a standard.
Glucose Uptake—Before transport experiments, cells were incubated
for 2 h in DMEM containing 0.2% bovine serum albumin. After this
time, cells were washed, and transport solution (20 mM Hepes, 150 mM
NaCl, 5 mM KCl, 5 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, 2 mM
pyruvate, pH 7.4) was added, together with 100 mM 2-deoxy-D-[3H]glu-
cose (96 mCi/mmol). After 20 min, transport was stopped by addition of
2 volumes of ice-cold 50 mM glucose in PBS. Cells were washed 3 times
in the same solution and disrupted with 0.1 M NaOH, 0.1% SDS.
Radioactivity was determined by scintillation counting. Protein was
determined by the Bradford method (28). Each condition was run in
duplicate, and the nonspecific uptake (t 5 0) was determined by incu-
bation of the 2-deoxy-D-[3H]glucose in stop solution (50 mM glucose in
PBS) instead of transport solution. In all cases, the value at t 5 0
represented 4% of the basal transport activity at t 5 20 min.
Electrophoresis and Immunoblotting—SDS-polyacrylamide gel elec-
trophoresis was performed in accordance with the method of Laemmli
(29). Proteins were transferred to Immobilon as reported (30). Transfer
was confirmed by Coomassie Blue staining of the gel after the electro-
blot. Rabbit Bb antiserum raised against the purified human erythro-
cyte glucose transporter (a gift of Dr. C. Carter-Su, University of Mich-
igan) was used at a 1:400 dilution and was incubated with transferred
protein overnight at room temperature in 1% nonfat dry milk, 0.02%
sodium azide in PBS to detect GLUT1. An anti-Sp1 affinity-purified
rabbit polyclonal antibody (PEP-2, Santa Cruz Biotechnology) was used
at a 5 mg/ml dilution in 1% nonfat dry milk, 0.02% sodium azide in PBS
and incubated overnight at 4 °C. Detection of the immune complexes
with the rabbit polyclonal antibodies was accomplished using 125I-
protein A for 4 h at room temperature or using the ECL Western blot
detection system (Amersham Corp.). Immunoblots were performed un-
der conditions in which autoradiographic detection was in the linear
response range.
RNA Isolation and Northern Blot Analysis—Total RNA was ex-
tracted using the acid guanidinium thiocyanate/phenol/chloroform
method as described by Chomczynski and Sacchi (31). All samples had
a A260/A280 ratio above 1.8. After quantification, total RNA (30 mg) was
denatured at 65 °C in the presence of formamide, formaldehyde, and
ethidium bromide to allow the visualization of RNA. RNA was sepa-
rated on a 1.2% agarose-formaldehyde gel and blotted on Hybond N
filters. The RNA in gels and in filters was visualized with ethidium
bromide by UV transillumination to ensure the integrity of RNA, to
check the loading of equivalent amounts of total RNA, and to confirm
proper transfer. Northern blot was performed as reported (27). The rat
cDNA probe for GLUT1 was a 2,521 fragment obtained from Dr. M.
Birnbaum (University of Pennsylvania) and was labeled with
[32P]dCTP by random oligonucleotide priming.
GLUT1 CAT Reporter Constructs—Plasmid 2,106/1134-CAT was
constructed by inserting a 2,240-bp EcoRI-XhoI fragment containing
the rat GLUT1 promoter region from positions 22,106 to 1134 (relative
to the transcription start site) into the XbaI site of pCAT-basic vector
(Promega). pCAT-basic was digested with XbaI, filling in of the ends
with dNTPs in the presence of the Klenow fragment, and treated with
alkaline phosphatase. The GLUT1 promoter DNA fragment was filled
in the presence of dNTPs and Klenow fragment and ligated to the
pCAT-basic vector. 59 deletions were generated by cleaving with Hin-
dIII at 21672 (21672/1134-CAT), with HindIII and BstEII (21203/
1134-CAT), with HindIII and BanII (2812/1134-CAT), with HindIII
and SmaI (2201/1134-CAT), and with HindIII and AocI (299/233-
CAT), adding Klenow and T4 DNA ligase. The 233/1134-CAT con-
struct was generated by obtaining a 28-bp HindIII-BssHII DNA con-
taining the fragment 238/215 from a 106-bp AvaII fragment (position
238/168) of the GLUT1 promoter subcloned in Bluescript. The 28-bp
fragment was subcloned into the BssHII site of the BssHII-G1CAT
construct (215/1134). The 39 deletion constructs were generated by
cleaving with XbaI and BfrI (22106/146-CAT) and with XbaI and
BssHII (12106/215-CAT).
Transient Transfection—250,000 L6E9 cells were grown in 10-mm
diameter plates for 2 days in DMEM with 10% fetal bovine serum.
Monolayers were washed, and DNA transfection was performed by
using the CaPO4 coprecipitation procedure (32). One ml of calcium
phosphate DNA precipitate containing 10 mg of various deletion pro-
moter-chloramphenicol acetyltransferase constructs, 5 mg of pCMV-b-
galactosidase control vector, and 20 mg of Bluescript DNA (pSK2, Strat-
agene), was added dropwise to the plate, and medium was added 15 min
later. After 16 h, the cells were washed and incubated with 1 ml of 15%
glycerol in Hepes-buffered saline for 3 min, washed with DMEM, and
incubated with fresh complete medium for 72 h. For the myotubes, the
medium was changed to differentiation medium (DMEM supplemented
with 2% fetal bovine serum) after the 15 min incubation with the DNA
precipitate.
Preparation of Cell Extracts and Measurement of CAT Activity—The
cells were washed 2 times with PBS and were harvested by scraping in
1 ml of STE (10 mM Tris-HCl, pH 7.5, containing 100 mM NaCl, and 1
mM EDTA). The cells were collected by centrifugation in a microcentri-
fuge for 10 min, and the pellet was resuspended in 200 ml of 0.25 M Tris,
pH 7.5. The cells were lysed by 3 cycles of freezing and thawing at 37 °C.
After centrifugation in a microcentrifuge for 5 min at 4 °C, the super-
natant was stored at 220 °C.
The CAT activity of 75 ml of cytoplasmic extract was measured by
incubating 0.1 mCi of 14C-chloramphenicol, 1.3 mM acetyl-CoA, 200 mM
Tris-HCl, pH 7.5, and the soluble extract for 3.5 h at 37 °C. At the end
of the incubation, extraction into ethyl acetate and thin layer chroma-
tography (33) were performed. The CAT activity was quantitated using
an InstantImager (Packard). b-Galactosidase activity was measured as
described (34).
Electrophoretic Mobility Shift Assay (EMSA)—Preparation of the
nuclear protein extracts was performed as described by Ausubel et al.
(35). The DNA probe (fragment 2102/237) was obtained by digesting
the 2201/1134-CAT construct with AvaII, purifying the 66-bp frag-
ment, and 32P-end-labeled using the Klenow fragment of the DNA
polymerase. The gel mobility shift assays were performed in a 12-ml
reaction volume, containing 2 mg of double-stranded poly(dI-dC), 15,000
cpm of labeled DNA probe, 5–10 mg of protein of nuclear extracts, 10 mM
Hepes, pH 7.9, 10% glycerol, 50 mM KCl, 0.1 mM EDTA, 0.1 mM phen-
ylmethylsulfonyl fluoride, and 0.25 mM dithiothreitol. The mixture
(without the labeled DNA) was incubated for 15 min at room tempera-
ture. After the addition of the labeled DNA, the reaction mixture was
incubated for another 10 min at 4 °C, immediately loaded on a 7%
polyacrylamide gel (30:0, 8 acrylamide-bis-acrylamide), and run in
0.5 3 TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA, pH 8) for
3–4 h at 8 V/cm. The gels were dried and autoradiographed.
For competition assays, varying concentrations of unlabeled probe
(fragment 2102/237) or the following oligonucleotides were used in the
reaction mixture prior to addition of extract: oligonucleotide I (2100/
282), 59-CCTCAGGCCCCGCCCCCCG-39; oligonucleotide I mutated,
59-CCTCAGGCCCCGTACCCCG-39; oligonucleotide 255/242, 59-GC-
GCGGGCCAATGG-39; and oligonucleotides containing the consen-
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sus site for Sp1 or AP2 (Promega).
Supershift experiments were performed by incubating nuclear ex-
tracts or commercial human recombinant Sp1 protein (Promega),
poly(dI-dC), and end-labeled probe as detailed above and then incu-
bated for 30 min at 4 °C in the presence of 1 mg of Sp1 antibody (PEP-2,
Santa Cruz Biotechnology) or with an irrelevant antibody. The samples
were loaded on a 4% polyacrylamide gel, dried, and autoradiographed.
RESULTS
Myogenesis Diminishes Glucose Transport and Represses
GLUT1 Expression and the Transcriptional Activity of the
GLUT1 Promoter—Differentiation of L6E9 myoblasts into
myotubes was associated with a diminished rate of basal glu-
cose transport (near 80% decrease) (Fig. 1). Under these con-
ditions, the total cellular content of GLUT1 glucose transporter
protein was also markedly reduced (levels in myotubes ac-
counted for 22 6 6% of values found in myoblasts) (Fig. 1). This
is in keeping with previous observations performed in L6 mus-
cle cells (21, 22). A reduction in GLUT1 mRNA levels was also
detected in L6E9 myotubes compared with myoblast cells (lev-
els in myotubes accounted for 33 6 3% of values found in
myoblasts) (Fig. 1). The reduction in GLUT1 protein and
mRNA occurred under conditions in which no changes in the
cellular content of b1-integrin protein or rRNA were detected
(data not shown).
To determine the basis for the repression of GLUT1 expres-
sion, myoblasts or myotubes were incubated in the presence of
actinomycin D (5 mg/ml) for different time periods, and the
levels of GLUT1 mRNA were assessed (Fig. 2A). Results indi-
cate that the half-life of GLUT1 mRNA species was near 5 h,
and no differences between myoblast and myotube cells were
detected (Fig. 2A). Therefore, the reduction in GLUT1 mRNA
levels during muscle cell differentiation is not due to alter-
ations in the stability of GLUT1 mRNA.
Next, myoblast or myotube cells were transiently transfected
with a fragment of the GLUT1 gene promoter (22106/1134)
fused to the reporter gene CAT. Cells transfected with the
reporter gene showed very low levels of CAT activity, similar to
those shown by non-transfected cells (Fig. 2B). Transfection
with the construct 22106/1134-CAT in L6E9 myoblasts caused
a 11.5-fold increase in CAT activity (Fig. 2B). Furthermore,
FIG. 1. Effect of muscle cell differentiation on glucose trans-
port and GLUT1 expression. A, after serum deprivation, L6E9 myo-
blasts and myotubes after 7 days of differentiation were incubated in
the presence of 0.1 mM 2-deoxy-[3H]glucose. The cellular hexose uptake
at t 5 20 min was measured as described under “Experimental Proce-
dures.” Differences between myoblasts (open bars) and myotubes (black
bars) were statistically significant at p , 0.05. B, membrane proteins
were purified from L6E9 myoblasts or myotubes after 4 or 7 days of
differentiation. 20 mg of membrane proteins were laid on gels. After
blotting, GLUT1 protein was detected by incubation with a polyclonal
antibody against the COOH terminus of the carrier. A representative
autoradiogram is shown. C, total RNA was purified from L6E9 myo-
blasts or myotubes after 4 or 7 days of differentiation. 20 mg of total
RNA were laid on gels. The integrity and the relative amounts of RNA
in each sample were checked by ethidium bromide staining on the same
gel. After blotting, GLUT1 mRNA was detected after hybridization with
a 2,521-base pair EcoRI fragment as a cDNA probe and as described
under “Experimental Procedures.” A representative autoradiogram is
shown.
FIG. 2. Myogenesis reduces the transcriptional activity of the
GLUT1 gene promoter in the absence of alterations in the half-
life of GLUT1 mRNA. A, L6E9 myoblasts (open symbols) and myo-
tubes (closed symbols) were incubated for different time periods in the
presence of 5 mg/ml actinomycin D. After different times, total RNA was
obtained, and GLUT1 mRNA levels were determined by Northern blot
(see details in legend to Fig. 1). Results were quantified and expressed
as a percentage of values at time 0. B, L6E9 myoblasts (open bars) or
myotubes (black bars) were transiently co-transfected by calcium phos-
phate precipitation with the 22106/1134-CAT construct (10 mg) or with
the promoterless pCAT-basic vector (10 mg) as indicated. 72 h after
transfection, cells were harvested and homogenized, and CAT activity
was determined. Data of CAT activity are expressed as a percentage of
acetylated chloramphenicol (mean 6 S.E.) from five to six experiments
performed in duplicate using at least two preparations of each DNA
construct.
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CAT activity detected in myotubes was substantially reduced
(60% decrease) compared with values in myoblasts (Fig. 2B).
These results indicate that the fragment 22106/1134 of the
GLUT1 gene contains information that is relevant to transcrip-
tional activity in the myoblast and that allows repression in
response to myogenesis.
Cis-elements Responsible for the Transcriptional Activity of
the GLUT1 Promoter and Effects of Myogenesis—To determine
the cis-elements involved in the transcriptional activity of the
GLUT1 promoter, 59 deletion constructs of the GLUT1 pro-
moter fused to the CAT reporter gene were generated and
transiently transfected in myoblast and myotube L6E9 cells
(Fig. 3).
Deletion from 22106 to 2812 of the GLUT1 gene caused no
significant alterations in CAT activity (Fig. 3), and deletion
from 2812 to 2201 caused nearly 60% stimulation of CAT
activity, suggesting a repressor element (Fig. 3). The transcrip-
tional activity of the 2201 construct was maximal and only a
slight decrease was noted after deletion from 2201 to 299.
However, deletion of a further 66 base pairs (from 299 to 233)
led to a marked reduction (80%) in the transcriptional activity.
The repression of transcriptional activity due to myogenesis
was maximal in the 299/1134 construct although some differ-
ences were still found in the 233/1134 construct (Fig. 3). The
233/1134 construct contains the TATA box, located at 232/
227 relative to the transcription start site (36).
To rule out the participation of the 39-end of the fragment of
the GLUT1 promoter which lies 39 of the transcription start
site, additional constructs were generated by 39 deletion (Fig.
4). Deletion of 88 base pairs lying between 1134 and 146
caused a 60% reduction in transcriptional activity (Fig. 4),
suggesting elements important for the transcriptional activity.
Under these conditions, myogenesis reduced the transcrip-
tional activity of all constructs studied (Fig. 4).
These data indicate that the fragment 299/233 is responsi-
ble for the transcriptional activity of the GLUT1 promoter.
Furthermore, this fragment, together with the fragment con-
taining the TATA box, seems to confer sensitivity to muscle cell
differentation.
Nuclear Proteins Bind to the 299/233 Fragment of the
GLUT1 Promoter in a Differentiation-dependent Manner—The
299/233 fragment of the GLUT1 gene contains one consensus
Sp1 site, two AP-2-like sites, and one CAAT box (Fig. 6). To
determine whether nuclear proteins bind to the fragment 299/
233 of the GLUT1 promoter, a DNA fragment encompassing
the sequence 2102/237 was radioactively labeled, and EMSA
FIG. 4. Effect of myogenesis on the
expression of GLUT1 3* deletion con-
structs in L6E9 cells. A series of 39 de-
letions of the upstream region of the
GLUT1 gene from 1134 to 215 bp rela-
tive to the transcription start site were
generated as indicated. L6E9 myoblasts
(open bars) or myotubes (black bars) were
transiently transfected with the various
constructs. 96 h after transfection, cells
were harvested. The data are expressed
as relative CAT activity/b-galactosidase
activity 6 S.E. from four to six experi-
ments with the 22104/1134-CAT con-
struct being set to a value of 100 (in the
myoblast group). These results were ob-
tained from transfection experiments per-
formed in duplicate using at least two
preparations of DNA. Differences be-
tween myoblasts and myotubes were sig-
nificant at p , 0.05.
FIG. 3. Effect of myogenesis on the
expression of GLUT1 5* deletion con-
structs in L6E9 cells. A series of 59 de-
letions of the upstream region of the
GLUT1 gene from 22106 to 233 bp rela-
tive to the transcription start site were
generated as indicated. L6E9 myoblasts
(open bars) or myotubes (black bars) were
transiently transfected with the various
constructs. 96 h after transfection, cells
were harvested. The data are expressed
as relative CAT activity/b-galactosidase
activity 6 S.E. from four to six experi-
ments with the 2201/1134-CAT con-
struct being set to a value of 100 (in the
myoblast group). These results were ob-
tained from transfection experiments per-
formed in duplicate using at least two
preparations of DNA. Differences be-
tween myoblasts and myotubes were sig-
nificant at p , 0.05.
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assays were performed in the presence of nuclear extracts
obtained from L6E9 myoblasts or myotubes (Fig. 5). A number
of specific bands was detected in nuclear extracts (Fig. 5). Some
of them, named A1, A2 and B, were restricted to myoblasts, and
others (complexes D1 and D2) were more abundant in myo-
blasts than in myotubes. In contrast, complexes C2 and D3
were more abundant in myotubes than in myoblasts (Fig. 5). C1
was the only complex to show a similar abundance in extracts
from myoblasts and from myotubes (Fig. 5).
To map the DNA elements that allowed the binding of the
different complexes, EMSA assays were performed in the pres-
ence of an excess of unlabeled oligonucleotides (Fig. 6). EMSA
assays performed in the presence of unlabeled oligonucleotide
2100/282 (oligonucleotide I), which contains the canonical Sp1
site, and an overlapping AP-2-like site displaced, in a concen-
tration-dependent manner, complexes A1 and A2 found in myo-
blast extracts (Fig. 7A). No bands were displaced in the pres-
ence of the canonical sequence corresponding to the AP-2 site or
with oligonucleotide 255/242, which contains the CAAT box
(data not shown).
Sp1 Binds and Transactivates the GLUT1 Promoter and Is
Repressed during Myogenesis—Next, we focused on the nature
of the complexes A1 and A2, characteristic of myoblast ex-
tracts. Based on the presence of a canonical Sp1 site in position
292/287, we searched whether binding of factors to this site
might be responsible for complexes A1 and A2. EMSA assays
were performed in the presence of an excess of unlabeled oli-
gonucleotides containing a canonical Sp1 site (Fig. 7A). Under
these conditions, complexes A1 and A2 were displaced very
efficiently in the presence of 100-fold molar excess of the oligo-
nucleotide Sp1 (Fig. 7A). Furthermore, the incubation in the
presence of an excess of oligonucleotide 2100/282 in which the
Sp1 site was mutated (Fig. 7A, oligonucleotide Imut) failed to
displace complexes A1 and A2 (Fig. 7A). Sp1 protein belongs to
a family of zinc-finger transcription factors (37, 38), and the
formation of complexes in band-shift assay is sensitive to the
presence of Zn21 or EDTA in the medium (39). Based on this,
gel-retardation analyses were performed in the absence or
presence of Zn21 or EDTA. The addition of Zn21 to the medium
increased the formation of complexes A1 and A2 in a
concentration-dependent manner (Fig. 7B). In contrast, addi-
tion of EDTA caused a concentration-dependent inhibition of
complexes A1 and A2 (Fig. 7B).
To confirm the binding of Sp1 protein, super shift assays
were also performed. To this end, EMSA assays were carried
out in the presence of an anti-Sp1 antibody. Due to the utili-
zation of a different percentage of polyacrylamide and due to a
longer electrophoresis run, the complex A1 previously seen as a
single broad band was resolved as two distinct complexes
(named A1 and A19) (Fig. 8). In these studies, recombinant Sp1
protein was also incubated with labeled fragment 2102/237
(Fig. 8). Results indicate that recombinant Sp1 forms a complex
with fragment 2102/237, which shows a retardation similar to
complex A1, and the formation of this complex was prevented
in the presence of an excess of oligonucleotide I (2100/282)
(Fig. 8). In addition, anti-Sp1 antibody eliminated part of com-
plex A1 and generated a complex showing a greater retarda-
tion. A similar super-retarded band was observed when recom-
binant Sp1 was incubated with anti-Sp1 antibody (Fig. 8).
These results indicate that endogenous Sp1 present in ex-
tracts from L6E9 myoblasts binds to the GLUT1 promoter. To
determine whether Sp1 modulates the transcriptional activity
of the GLUT1 promoter, L6E9 myoblasts or myotubes were
co-transfected with the construct 22106/1134-CAT and the
cDNA coding for Sp1. Sp1 caused a large transactivation of the
GLUT1 promoter activity (4.9-fold increase) in myoblasts (Fig.
9). In addition, Sp1 activated the GLUT1 promoter activity in
myotubes; however, the transcriptional activity detected in
myoblasts was much greater than in myotubes (Fig. 9).
We have found that Sp1 protein binds to the GLUT1 gene
promoter in myoblasts but not in myotubes. To determine the
nature of the mechanisms involved, we determined the level of
Sp1 protein in nuclear extracts obtained from L6E9 myoblasts
and myotubes (Fig. 10). Sp1 protein was observed in Western
blot as two bands with an apparent molecular masses of 105
and 95 kDa, which is in keeping with previous observations (40,
41). The content of Sp1 protein in myoblasts was much greater
than in myotubes (Fig. 10) (levels of Sp1 protein in myotubes
accounted for 27 6 10% of values found in myoblasts). This
effect was specific since the abundance of the transcription
factor STAT-1 was similar in preparations from myoblasts or
myotubes (data not shown).
Over-expression of MyoD Represses Sp1 and Inhibits the
Transcriptional Activity of the GLUT1 Gene Promoter—The
best characterized factors that regulate the terminal differen-
tiation of the muscle cells are the members of the MyoD family.
To determine whether MyoD plays a role in the regulation of
GLUT1 gene expression during myogenesis, we studied the
effect of the stable over-expression of MyoD in C3H10T1/2 cells.
The stable expression of MyoD in these cells caused a marked
reduction in the transcriptional activity of the GLUT1 pro-
FIG. 5. Specific binding of nuclear factors from L6E9 myo-
blasts and myotubes to the 2102/237-bp GLUT1 DNA fragment.
Labeled AvaII-AvaII fragment (2102/237) was incubated with 5 mg of
nuclear extracts either from L6E9 myoblasts (MB) or myotubes (MT)
after 7 days of differentiation and analyzed on a 7% polyacrylamide gel.
The specificity of the complex formation was examined by addition of
the 100 M excess of the unlabeled 2102/237 fragment used as a com-
petitor. A representative autoradiogram is shown. Arrows indicate spe-
cific complexes.
FIG. 6. Scheme of the fragment 2102/237 of the GLUT1 pro-
moter and oligonucleotides used as competitors. Boxes indicate
the consensus sequences for Sp1, AP-2, and CAAT boxes.
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moter as assessed by transient transfection of the 22106/1134-
CAT construct (CAT activity levels in C3H10T1/2 wild type and
C3H10T1/2-MyoD were 43 6 3 and 15 6 3, respectively, ex-
pressed as arbitrary units and corrected per b-galactosidase
activity).
EMSA assays revealed the presence of highly retarded com-
plexes in nuclear extracts from C3H10T1/2 cells that showed
similar mobility to complexes A1 and A2 from L6E9 myoblasts.
Furthermore, these complexes were competed with an oligonu-
cleotide containing the consensus sequence for Sp1 binding
(Fig. 11) and with oligonucleotide I (2100/282) (data not
shown). Stable over-expression of MyoD caused the disappear-
ance of the complex binding to the Sp1 element (Fig. 11) and
the formation of low-retarded complexes (Fig. 11). Further-
more, Western blot assays of Sp1 protein from nuclear extracts
FIG. 7. Characterization of factors binding to the Sp1 element of the GLUT1 gene. Labeled AvaII-AvaII fragment (2102/237) was
incubated with 5 mg of nuclear extracts from L6E9 myoblasts (MB) and analyzed on a 7% polyacrylamide gel. A, the specificity of the complexes
A1 and A2 formation was examined by addition of a molar excess of unlabeled competitors containing a canonical Sp1 site (Sp1, molar excesses
of 100, 200, and 400), oligonucleotide I (2100/282), oligonucleotide 2100/282 containing a mutated Sp1 site (Imut, molar excesses of 500, 1000,
and 2500), or the unlabeled 2102/237 fragment (CP, 100-fold M excess). B, binding of nuclear factors to the labeled fragment was performed after
the addition of different concentrations of Zn21 or EDTA. Representative autoradiograms are shown.
FIG. 8. Sp1 binds to the 2102/237-bp GLUT1 DNA fragment.
Labeled AvaII-AvaII fragment (2102/237) was incubated with 5 mg of
nuclear extracts from L6E9 myoblasts in the presence of an Sp1 antibody
(Sp1) or an irrelevant antibody (IgG) and analyzed on a 4% polyacryl-
amide gel. The recombinant Sp1 protein (0.5 mg) was also incubated with
the labeled AvaII-AvaII fragment (2102/237) in the presence of an Sp1
antibody, an irrelevant antibody, or oligonucleotide I (2100/285) at a
1,000-fold M excess. Due to the utilization of a different percentage of
polyacrylamide and due to a longer electrophoresis run, the complex A1
previously seen as a single broad band was resolved as two distinct
complexes (named A1 and A19). A representative autoradiogram is shown.
FIG. 9. Sp1 transactivates the GLUT1 promoter. L6E9 myoblasts
or myotubes were transiently co-transfected by calcium phosphate pre-
cipitation with the 22106/1134-CAT construct (10 mg) or with the
promoterless pCAT-basic vector (10 mg) in the absence or presence of an
expression vector coding for Sp1 (CMV-Sp1) (10 mg). 96 h after trans-
fection, cells were harvested and homogenized, and CAT activity was
determined. Data are expressed as CAT activity/mg of protein (mean 6
S.E.) from three experiments performed in duplicate using at least two
preparations of each DNA construct. Open bars, myoblast; hatched
bars, myoblasts 1 Sp1; black bars, myotubes; gray bars, myotubes 1
Sp1.
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obtained from wild-type C3H10T1/2 and C3H10T1/2-MyoD
cells indicated a dramatic down-regulation of Sp1 protein
after MyoD over-expression (Fig. 11). These results suggest a
role of MyoD in the down-regulation of Sp1 associated with
myogenesis.
DISCUSSION
In this study, we have demonstrated that GLUT1 is re-
pressed in muscle cells during differentiation as a consequence
of alterations in transcriptional activity of the GLUT1 gene,
which seems to involve the fragment 299/233 and the frag-
ment 59 proximal to the transcription start site containing the
TATA box. Furthermore, the levels of GLUT1 mRNA and the
transcriptional activity of the GLUT1 promoter were similarly
reduced in response to myogenesis; this suggests that the al-
terations in the transcriptional activity of the GLUT1 promoter
are sufficient to account for the GLUT1 repression. In the
region 299/233 of the GLUT1 gene, we have identified the
binding of Sp1 to the GLUT1 gene promoter; this seems to be
important from a functional viewpoint since Sp1 transacti-
vates, in transient transfection assays, the transcriptional ac-
tivity of GLUT1 promoter. In contrast to the current view
stating that Sp1 is a ubiquitous factor, we have found that
myogenesis leads to a drastic reduction in the formation of a
DNA-protein complex involving Sp1, which is due to a marked
down-regulation of Sp1 expression. Our results also indicate
that MyoD over-expression down-regulates Sp1 expression in
cells, which is in parallel to a reduction in the transcriptional
activity of the GLUT1 gene. Based on this, we propose the
model depicted in Fig. 12. According to this, the transcriptional
activity of the GLUT1 gene is high in proliferating myoblasts,
in part due to a high expression of the activator Sp1. Muscle
cell differentiation is associated with activation of MyoD tran-
scription factors, which act as master regulators leading to
activation of many muscle-specific genes. In our model, Myo D
activation leads to the repression of Sp1 expression in muscle
cells. In turn, Sp1 down-regulation causes inactivation of the
transcriptional activity of the GLUT1 gene and, therefore,
leads to GLUT1 down-regulation and to a diminished rate of
glucose transport. A prior report indicates that an Sp1-site is
required for the expression of Id (an inhibitory factor of MyoD
function) in muscle cells (18). Based on this, we additionally
postulate that Sp1 down-regulation contributes to the repres-
sion of Id found during myogenesis and which is known to
participate in the activation of myogenic transcription factors
(17, 42).
Prior studies on the regulation of the GLUT1 gene have
exclusively focused on the functional role of two enhancer ele-
ments found in the mouse GLUT1 gene. The first enhancer has
been located 2.7 kilobases upstream of the transcription start
site, whereas the second is in the second intron of the gene (43).
These enhancers permit the activation of the transcription in
response to growth factors, insulin, or hypoxia (43–45). Here,
we have analyzed the properties of the proximal promoter of
the rat GLUT1 gene. Our results indicate the presence of a
repressor element located in the fragment 2812/2201 that is
active both in myoblasts and in myotubes. Our data also sug-
gest that the fragment close to the TATA box or the TATA box
itself participates in the repression of GLUT1 transcription
during myogenesis. In this regard, it has been reported that
factors such as TEF-1 or NC2 block the formation of TBP-TATA
complexes and inhibit gene transcription (46, 47). Whether
some of these factors play a role through the TATA box in the
regulation of the GLUT1 gene during myogenesis remains
unknown.
FIG. 10. Expression of Sp1 protein in nuclear extracts from
myoblasts and myotubes. Nuclear factors were obtained from L6E9
myoblasts (MB) or myotubes (MT). 20 mg of nuclear extracts were laid
on gels. After blotting, Sp1 protein was detected by incubation with a
specific polyclonal antibody. A representative autoradiogram is shown.
FIG. 11. Over-expression of MyoD represses Sp1 expression
and formation of complexes with the 2102/237 bp of the GLUT1
gene. A, labeled AvaII-AvaII fragment (2102/237) was incubated with
5 mg of nuclear extracts either from wild-type C3H10T1/2 cells (WT) or
C3H10T1/2 cells stably transfected with MyoD (MyoD) and analyzed on
a 7% polyacrylamide gel. The specificity of the complex formation was
examined by addition of a 100 M excess of the unlabeled 2102/237
fragment (CP) or a 200 M excess of unlabeled oligonucleotide containing
a canonical Sp1 site used (SP1) as competitors. B, nuclear factors were
obtained from wild-type C3H10T1/2 cells (WT) or C3H10T1/2 cells
stably transfected with MyoD (MyoD). 20 mg of nuclear extracts were
laid on gels. After blotting, Sp1 protein was detected by incubation with
a specific polyclonal antibody. Representative autoradiograms are
shown.
FIG. 12. Hypothetical scheme of the mechanisms responsible
for the repression of GLUT1 gene expression during
myogenesis.
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Furthermore, we have identified the fragment 299/233 of
the GLUT1 gene that is responsible for the transcriptional
activity of the GLUT1 promoter. We have also identified the
presence of different complexes found in myoblasts or myotube
nuclear extracts and that bind to the 299/233 region. Specif-
ically, we have identified high-retardation complexes (named
A1 and A2) that are restricted to myoblasts. Based on the
selective competition of these bands to oligonucleotides con-
taining the Sp1 binding site, the sensitivity of these complexes
to Zn21 and EDTA, the fact that they show a similar retarda-
tion to recombinant Sp1, and that there is a super-shift in the
presence of an antibody against Sp1, we propose that Sp1
participates in the formation of these complexes.
In our study, we have found that Sp1 stimulates the tran-
scriptional activity of the GLUT1 gene 5-fold in transient
transfection assays. These data, together with the fact that
there is a high expression level of Sp1 protein in nuclear ex-
tracts obtained from myoblasts and that Sp1 binds to the
fragment 299/233 selectively in myoblasts, strongly support
the hypothesis that Sp1 regulates GLUT1 transcription in
muscle cells. Interestingly, the binding of Sp1 protein to the
GLUT1 promoter correlates with a high GLUT1 gene expres-
sion in a variety of experimental conditions.2 The transient
transfection of Sp1 into myotubes led to a stimulation of the
GLUT1 rate of transcription that was markedly lower than
that obtained in myoblasts. These results suggest a defect of
Sp1 action in myotube cells. In this regard, it has been shown
that Sp1 forms heteromeric complexes with several cellular
proteins. The TATA-binding protein protein-associated protein
TAF110 binds Sp1 and functions as a co-activator in Sp1-de-
pendent transcription (37). Sp1 also interacts with the cellular
protein YY1 (48, 49), with the RelA subunit of NF-kB (50), and
with the bovine papilloma virus (51). Based on the fact that the
cotransfection of a retinoblastoma expression vector is able to
modulate the transactivation of responsive genes by Sp1, the
function of Sp1 has been linked to that of the retinoblastoma
protein (52, 53) through retinoblastoma control elements. Some
mechanisms of inhibition of Sp1 action have also been reported.
Thus, the cell-cycle-regulatory protein 107 can be found endo-
genously associated with Sp1 and, in cotransfection assays,
p107 specifically represses Sp1-dependent transcription (41).
Furthermore, G10BP protein or Sp3 competes with Sp1 for
G-rich sequences and inhibits Sp1 action (54–56). Based on all
these items of information, it might be postulated that myo-
genesis not only leads to Sp1 down-regulation but also causes
alteration in the biological potency of Sp1, which might be
explained either by alterations in the proteins that allow the
formation of active complexes or due to the presence of Sp1-
binding inhibitory proteins.
Sp1 is thought to be a ubiquitously expressed transcription
factor that plays a primary role in the regulation of a large
number of genes, including constitutive housekeeping genes
and inducible genes (57). Recent studies indicate that Sp1 is a
limiting factor in cultured cells and that overexpression of Sp1
increases expression from promoters containing GC-box ele-
ments (58). Additionally, there is evidence that Sp1 expression
is regulated. Thus, Sp1 levels increase during SV40 infection of
the CV1 cells (58). Furthermore, it has been reported that Sp1
expression varies greatly in different cell types and changes in
Sp1 occur during development in vivo (59). Thus, high levels of
Sp1 expression were found in spermatids, T cells, epithelial
cells and hematopoietic cells (59). Interestingly, the expression
of Sp1 mRNA in heart and skeletal muscles was higher in early
neonatal mice than in adult animals (59). Along these lines, we
have found in this study that myogenesis greatly alters the
expression of Sp1 in muscle cells. Furthermore, our results
support the view that MyoD causes down-regulation of Sp1 in
stable transfection assays. In summary, we propose that acti-
vation of MyoD transcription factors causes down-regulation of
Sp1 protein, and this might be one the mechanisms that lead to
GLUT1 repression and accomplishment of the differentiation
program in the muscle cell. The mechanisms underlying Sp1
down-regulation in response to MyoD transcription factors are
currently under study in our laboratory.
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